Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types
Go back to Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 125.31 -2.31 (1.81%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $127.62 | 52 Week High | $118.49 | |||
| Open | $127.85 | 52 Week Low | $55.00 | |||
| Day High | $128.72 | P/E | N/A | |||
| Day Low | $125.23 | EPS | $-0.56 | |||
| Volume | 3,700,410 | |||||
